Saturday, March 07, 2015 12:15:05 PM
We have to remember, MAV is not the revenue stream. Compounding pharmacy is. I see future PRs stating "SCRC's monthly revenues for compounding were $6M" versus "MAV reported x-amount of revenues".
Mr. Schneiderman also highlighted the importance of a diversified product line with "PIMD, the Diabetic Medical Supplies line, additional pharmacies, and, prospectively, a Physician dispensing program", all of which will impact profitability. We already saw the impact PIMD ($554K) and Diabetes ($103K) in this week's PRs. Notice too, he mentions additional pharmacies. In reference to what I wrote in the above paragraph, this guy knows what he's doing. I am excited to hear more about the physician dispensing program. Being in the pharma industry for over 37 years, I can tell you, this has enormous potential.
Do I like the decision from one insurance carrier to not reimburse – NO, absolutely not! Do I like what Mr. Schneiderman is doing to maintain and grow the revenue stream – YES, definitely! Plus, let’s not forget about RapiMeds. I know it’s a sore subject for some, but as long as Mr. Schneiderman believes RapiMeds will be a reality, so do I.
My bottom line - SCRC is stronger now as a company then ever before.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM